Morningstar: Bayer, Merck & Co's Heart-Failure Drug Fails to Meet Target in Late-Stage Trial Bayer and Merck & Co, Inc. said heart-failure drug candidate vericiguat didn't meet the primary target of a late-stage study. The German conglomerate on Monday said vericiguat in the phase 3 Victor ...
Bayer, Merck & Co's Heart-Failure Drug Fails to Meet Target in Late-Stage Trial The American Journal of Managed Care: Heart Failure Stages and Impact of Delayed Diagnosis Panelists discuss how heart failure classification involves HFrEF vs HFpEF distinctions and staging systems (A through D), with the greatest prevention opportunities existing in early stages A and B, ... Seeking Alpha: Alnylam to advance Roche-partnered heart drug to late-stage trial despite mid-stage setback Alnylam Pharmaceuticals (NASDAQ:ALNY) announced on Saturday that the company and its partner Roche (OTCQX:RHHBY) would begin a late-stage trial for its experimental heart disease therapy, zilebesiran, ... Alnylam to advance Roche-partnered heart drug to late-stage trial despite mid-stage setback MSN: Ignoring these 7 early symptoms of heart failure can be fatal: Cardiologist urges to watch for quiet signs before it’s too late Ignoring these 7 early symptoms of heart failure can be fatal: Cardiologist urges to watch for quiet signs before it’s too late
